Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Tetsuhiro Yoshinami¹, Kazuki Nozawa², Takamichi Yokoe³, Yukinori Ozaki⁴, Hiroshi Nishio⁵, Kenji Tsuchihashi⁶, Eiki Ichihara⁷, Yuji Miura⁸, Makoto Endo⁹, Shingo Yano¹⁰, Dai Maruyama¹¹, Nobuyuki Susumu¹², Munetaka Takekuma¹³, Takashi Motohashi¹⁴, Mamoru Ito⁶, Eishi Baba¹⁵, Nobuaki Ochi¹⁶, Toshio Kubo¹⁷, Keita Uchino¹⁸, Takahiro Kimura¹⁹, Yutaro Kamiyama²⁰, Shinji Nakao²¹, Shinobu Tamura²², Hitomi Nishimoto²³, Yasuhisa Kato²⁴, Atsushi Sato²⁵, Toshimi Takano⁴

Affiliations

¹ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.
² Department of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
³ Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
⁵ Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
⁶ Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
⁷ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁸ Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
⁹ Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
¹⁰ Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
¹¹ Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
¹² Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
¹³ Deparment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
¹⁴ Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
¹⁵ Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁶ Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
¹⁷ Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
¹⁸ Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
¹⁹ Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
²⁰ Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
²¹ Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
²² Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
²³ Department of Nursing, Okayama University Hospital, Okayama, Japan.
²⁴ Department of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
²⁵ Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.

PMID: 38649648
DOI: 10.1007/s10147-024-02504-4

Meta-Analysis

Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Tetsuhiro Yoshinami et al. Int J Clin Oncol. 2024 Jun.

. 2024 Jun;29(6):681-688.

doi: 10.1007/s10147-024-02504-4. Epub 2024 Apr 23.

Authors

Affiliations

¹ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. yosinami-te@onsurg.med.osaka-u.ac.jp.
² Department of Center for Cancer Genomics and Advanced Therapeutics, Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
³ Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
⁵ Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
⁶ Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
⁷ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁸ Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
⁹ Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
¹⁰ Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
¹¹ Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
¹² Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
¹³ Deparment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
¹⁴ Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
¹⁵ Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁶ Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
¹⁷ Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
¹⁸ Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
¹⁹ Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
²⁰ Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
²¹ Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
²² Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
²³ Department of Nursing, Okayama University Hospital, Okayama, Japan.
²⁴ Department of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
²⁵ Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.

PMID: 38649648
DOI: 10.1007/s10147-024-02504-4

Abstract

Backgroud: Granulocyte colony-stimulating factor (G-CSF) is widely used for the primary prophylaxis of febrile neutropenia (FN). Two types of G-CSF are available in Japan, namely G-CSF chemically bound to polyethylene glycol (PEG G-CSF), which provides long-lasting effects with a single dose, and non-polyethylene glycol-bound G-CSF (non-PEG G-CSF), which must be sequentially administrated for several days.

Methods: This current study investigated the utility of these treatments for the primary prophylaxis of FN through a systematic review of the literature. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis or meta-analysis was conducted to evaluate six outcomes.

Results: Through the first and second screenings, 23 and 18 articles were extracted for qualitative synthesis and meta-analysis, respectively. The incidence of FN was significantly lower in the PEG G-CSF group than in the non-PEG G-CSF group with a strong quality/certainty of evidence. The differences in other outcomes, such as overall survival, infection-related mortality, the duration of neutropenia (less than 500/μL), quality of life, and pain, were not apparent.

Conclusions: A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.

Keywords: Meta-analysis; Multiple doses; Non-PEG G-CSF; PEG G-CSF; Single dose.

PubMed Disclaimer

References

1. Crawford J, Caserta C, Roila F et al (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. https://doi.org/10.1093/annonc/mdq195 - DOI - PubMed
1. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013 - DOI - PubMed
1. Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199–3212. https://doi.org/10.1200/JCO.2015.62.3488 - DOI - PubMed
1. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors Version 2. 2023
1. Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295–306. https://doi.org/10.2165/11586040-000000000-00000 - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Affiliations

Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous